ArticleAnnals of the rheumatic diseases2017

Correction: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.